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Abstract: 
Glioblastoma multiforme (GBM) is considered to be the most common and often deadly disorder which affects the brain. It is caused by the over expression of 
proteins such as ephrin type-A receptor 2 (EphA2), epidermal growth factor receptor (EGFR) and EGFRvIII. These 3 proteins are considered to be the potential 
therapeutic targets for GBM. Among these, EphA2 is reported to be over-expressed in ~90% of GBM. Herein we selected 35 compounds from marine 
actinomycetes, 5 in vitro and in vivo studied drug candidates and 4 commercially available drugs for GBM which were identified from literature and analysed by 
using comparative docking studies. Based on the glide scores and other in silico parameters available in Schrödinger, two selected marine actinomycetes 
compounds which include Tetracenomycin D and Chartreusin exhibited better binding energy among all the compounds studied in comparative docking. In this 
study we have demonstrated the inhibition of the 3 selected targets by the two bioactive compounds from marine actinomycetes through in-silico docking studies. 
Furthermore molecular dynamics simulation were also been performed to check the stability and the amino acids interacted with the 3 molecular targets (EphA2 
receptor, EGFR, EGFRvIII) for GBM. Our results suggest that Tetracinomycin D and Chartreusin are the novel and potential inhibitor for the treatment of GBM.  
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Background: 
Glioblastoma multiforme (GBM) is the most common and aggressive type of 
primary brain  tumor in  humans  [1]. GBM is a fast-growing type of central 
nervous system (CNS) tumor arises mainly from glial tissue of the brain and 
spinal cord. GBM usually occurs in adults and affects the brain more often than 
the spinal cord [2]. It has been proved that 17,000 primary brain tumors 
diagnosed in the United States each year, out of which approximately 60% are 
gliomas [3]. Gliomas are a group of central nervous system (CNS) neoplasms 
with various histological characteristics. They are classified into two major 
groups as astrocytomas and oligodendrogliomas based on their morphological 
and histological resemblances between malignant and normal cells [4]. The 
most common form of gliomas in human is the astrocytoma, and the most 
aggressive type is GBM [5].  
 
Molecular markers that are found on tumour cells and are also over-expressed 
on malignant cells were nearly absent on normal cells which facilitates as 
attractive drug targets. Along these lines we found ephrin-A2 (EphA2), 
epidermal growth factor receptor (EGFR) and EGFRvIII are considered to be 
novel molecular targets for this pathological condition, because it is expressed 
in high quantities in GBM [6]. EphA2 is a type of tyrosine kinase family [3] 
and this receptor is over expressed in various cancers of brain, breast, cervix, 
colon, oesophagus, head, neck, liver, lungs, ovary and skin [7-16]. The EphA2 
is believed to be an ultimate target in many cancers [17]. It plays a critical role 
in embryonic patterning, neuronal targeting, and vascular development during 
normal embryogenesis, cell proliferation and migration [18]. Eph receptor 
tyrosine kinases (Eph RTKs) and their ligands, ephrins are frequently over 
expressed in a various types of cancer and tumor [19]. About fourteen Eph 
receptor and eight ephrin ligands are involved in the various type of cancer [20-
21]. In vitro study has shown that modifications or a mutation in the EphA2 is 
responsible for GBM [22].  
 
EGFR is also a member of tyrosine kinase family containing proteins and it 
plays a major role in signal transduction pathway responsible for cell 
differentiation and proliferation [23]. Over expression of EGFR in GBM has 
been proven in many in vitro and in vivo studies [24]. It is also been over 
expressed in 50-60% of gliomas [25]. EGFRvIII is over expressed in most 24-
67% of glioblastoma patients [25]. This is a mutated type of the tyrosine kinase 
receptor. This is caused by genetic loss of 270 amino acids from the EGFR. 
This mutated type protein is responsible for GBM disease in humans [24].  
Multimodality therapy for this disease still remains unsatisfied [26]. In this 
study we adopted cheminformatics-based drug design approach to identify 
potential inhibitors against GBM. We conducted comparative docking studies 
using molecular modelling approach against a total of 44 drug-like molecules 
which includes (i) 35 drug-like molecules from the marine actinomycetes were 
selected through the available literature [27], (ii) 5 drug-like molecules which 
are currently under in vitro and in vivo investigations [28-31] and (iii) 4 known 
commercially available inhibitors [32-35] were docked against the 3 molecular 
targets including EphA2, EGFR and EGFRvIII.  From the docking experiments BIOINFORMATION  open access 
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data obtained, we identified two potential bioactive drug-like molecules out of 
35 ligands based on their better binding energies and pharmacokinetic 
properties than the other compounds utilized in this study. 
 
Methodology: 
Protein preparation of the 3 molecular targets of GBM: 
Docking studies were conducted on the three dimensional (3D) structures of 
the 3 molecular targets including EphA2, EGFR and EGFRvIII (PDB ID: 
1MQB, 1M17 and 1I8I) which were obtained from protein data bank [36]. 
Before performing docking, hydrogen atoms and charges were added to these 
crystal structures of 1MQB, 1M17 and 1I8I and then the complex was 
submitted to a series of restrained, partial minimizations using the optimized 
potential for liquid simulations-all atom (OPLS-2005) force field [37]. The 3D 
structures were then processed by use of the ‘Protein Preparation module’ with 
the ‘preparation and refinement’ option before docking. The missing loops in 
the structures were then filled in the respective protein molecules with the help 
of Prime, version 2.1 (Schrödinger, LLC, New York, 2009) [38]. Hydrogen 
atoms were added and all unwanted water molecules were removed from the 
structure. Partial charges were assigned according to OPLS-2005 force field. 
Charges and atom types were assigned.  
 
Binding site prediction for EGFRvIII: 
The binding sites for 1MQB and 1M17 were determined using PDBsum 
(http://www.ebi.ac.uk/pdbsum/). Since the active for EGFRvIII was not well 
defined; its binding site was predicted using SiteMap, version 2.3 (Schrödinger, 
LLC, NewYork, 2009) [38]. The SiteMap predicts the binding site in three 
stages, (i) a grid was assigned, and the points were grouped into sets according 
to various criteria to define the sites, (ii) the sites were mapped on another grid 
to produce files for visualization of the maps and (iii) finally, the properties 
were evaluated and sites has been written in a maestro-readable form. Each 
stage is accomplished by running an impact job and finally the best site was 
considered for the further docking study.  
 
Ligand structure Preparation: 
The 35 marine actinomycetes compounds which were retrieved from the 
literature [27], the chemical structures of these molecules were downloaded 
from PubChem (http://pubchem.ncbi.nlm.nih.gov/), few of these structures are 
not available in PubChem, hence we used ChemSketch version 
11.01  (http://www.acdlabs.com) to draw those structures. The chemical 
structures of the 5 compounds which are under in vitro and in vivo 
investigation along with the 4 commercially available compounds were also 
downloaded from PubChem and all these ligands were prepared for docking by 
using LigPrep, version 2.3 [38]. The tautomers for each of these ligands were 
generated and optimized. Partial atomic charges were computed using the 
OPLS-2005 force field. 
 
Docking using Glide extra precision: 
All the ligands which were prepared using LigPrep were then subjected for 
docking against the 3 molecular targets including EphA2, EGFR and EGFRvIII 
(PDB ID: 1MQB, 1M17 and 1I8I) using Glide extra-precision (XP), version 
5.5 [38] mode. The grid-enclosing box was centered to the active sites of the 
corresponding 3D-structures of these 3 molecular targets to GBM; so as to 
enclose them within 3 Å from the centroid of these residues. A scaling factor of 
1.0 was set to van der Waals (VDW) radii for these residue atoms, with the 
partial atomic charge less than 0.25. Glide XP mode determines all reasonable 
conformations for each low-energy conformer in the designated binding site. In 
the process, torsional degrees of each ligand are relaxed, though the protein 
conformation is fixed. During the docking process, the glide scoring function 
(G-score) was used to select the best conformation for each ligand. Final G-
scores were analysed based on the conformation at which the ligands formed 
hydrogen bonds to at least one of the active site amino acid residues of the 
corresponding 3D-structures of these 3 molecular targets with optimal binding 
affinity. Herein, the data obtained from these dockings were used to analyse the 
molecular interactions and also to identify the residues involved in hydrogen 
bond formation with 1MQB, 1M17, and 1I8I. The glide scores and energies 
including van der Waals (VDW) and electrostatic were calculated for all the 
ligands against EphA2, EGFR and EGFRvIII. Finally the molecular 
interactions and functional role of the two selected marine actinomycetes 
compounds named and the commercially available drugs were proposed in 
detail. All these docking procedures were performed on a Dell RHEL 5.0 
workstation. 
 
Molecular Dynamics Simulation: 
Molecular Dynamics simulations were done with all the 3 molecular targets of 
GBM against the two selected bioactive compounds. The MD simulation was 
performed by using Gromacs 3.3.2 [39, 40]. It works based on the leap-frog 
algorithm to integrate Newton equations. The NPT ensemble and Gromos96 
force field were applied to the system. Each docking complex was placed in the 
center of a 72 Å × 72 Å × 72 Å cubic box and solvated by simple point charge 
water molecules (SPC/E). Na
+ counter ions were added to keep the system 
electrically neutral and the periodic boundary condition was also applied to the 
system. Energy minimization was carried out by using steepest-descent method 
[41]. Berendsen temperature and pressure coupling methods were applied to 
keep the system in stable environment (300 K, 1 Bar), and the coupling 
constants were set at 0.1 and 1.0 for temperature and pressure respectively. 
Cut-off method was employed for electrostatic and van der walls interactions; 
cut-off distance for the short-range neighbor list (rlist) and was set at 0.8, 
whereas coulomb cut-off (rcoulomb) and VDW cut-off (rvdw) was fixed at 1.4. 
The LINCS algorithm was used to constraint the bonds [42]. The simulation 
was performed with a time step of 2fs and the coordinates were saved every 
1000 steps. 20 ps position restraining dynamics simulation was carried to 
relieve close contacts and to equilibrate the protein in the medium; finally 1ns 
molecular dynamics simulation and further analysis were performed. The 
dynamics results were visualized using VMD [43].  
 
Assessment of drug-like properties of selected optimized ligands: 
The selected optimized molecules were studied for their drug-like properties 
based on Lipinski parameters using QikProp version 3.2 [38], and also the 
percentage of their human oral absorption was also predicted to determine the 
toxicity levels, by use of QikProp [37].  
 
 
Figure 1: Illustration of binding pocket of bioactive compounds and drug 
targets a) EphA2 –Tetracenomycin D, b) EphA2- Chartreusin, c) EGFR- 
Tetracenomycin D, d) EGFR- Chartreusin, e) EGFRvIII –Tetracenomycin D 
and f) EGFRvIII- Chartreusin. Binding poses of the six lead molecules. The 
proposed binding modes of the two bioactive compounds with 3 molecular 
targets of the GBM are shown. The two bioactive compounds are shown in ball 
and stick display. Critical residues for binding are shown as sticks colored by 
atom types. Hydrogen bonds are shown as dotted pink lines with the distance 
between donor and acceptor atoms indicated. Atom type colour code: red for 
oxygen, blue for nitrogen, grey for carbon and yellow for sulphur atoms 
respectively. (a) The EphA2 docked with the Tetracenomycin D. (b) The 
EphA2 docked with the Chartreusin. (c) The EGFR docked with the 
Tetracenomycin D. (d) The EGFR docked with the Chartreusin. (e) The 
EGFRvIII docked with the Tetracenomycin D. (f) The EGFRvIII docked with 
the Chartreusin. BIOINFORMATION  open access 
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Results and Discussion: 
In this study, we conducted a comparative docking and molecular dynamics 
simulation between the two selected bioactive molecules that include 
Tetracenomycin D and Chartreusin which was  obtained from 35 marine 
actinomycetes compounds along with the 5 compounds derived from the 
experimental studies and 4 commercially available drugs against GBM. The in 
silico results revealed that the two bioactive molecules exhibited better binding 
affinity than the commercially available drugs against the 3 molecular targets 
of GBM including EphA2, EGFR and EGFRvIII. 
 
Binding site analysis for the molecular targets against GBM: 
The binding site for the two molecular targets including EphA2 and EGFR 
(PDB ID: 1MQB, 1M17) are known and were determined using PDBsum. But 
EGFRvIII (PDB ID: 1I8I) does not have any defined active site and hence it 
was predicted using SiteMap program in Schrödinger. The predicted amino 
acids were identified to be Asp408, Gln412, Trp410, Phe46, Gln301, Val302, 
and Gln412. Docking studies were performed with the two bioactive molecules 
against the 3 molecular targets based on their corresponding co-crystallized 
ligands available in their 3D-structures. All binding pockets of protein- ligand 
complexes were shown in the Figure 1.  
 
Analysis of Glide XP and Molecular Dynamics simulation results: 
The comparative docking analysis on the 35 marine actinomycetes [27], 5 in 
vitro and in vivo [36-39] compounds including i) Nimodipine- 3-(2-
methoxyethyl) 5-propan-2-yl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-
dihydropyridine-3,5-dicarboxylate, (ii) Gallic acid - 3,4,5-trihydroxybenzoic 
acid, (iii) Verapamil- (RS)-2-(3,4-dimethoxyphenyl)-5-{2-(3,4-
dimethoxyphenyl)ethyl-(methyl)amino}-2-prop-2ylpentanenitrile, (iv) Perrilyl 
alcohol-( (4-prop-1-en-2-yl-1-cyclohexenyl) methanol), (v) Gambogic acid and 
4 known commercial inhibitors [40-43] including Temazolomide, Sunitinib, 
Carmustine and Thalidomide (Supplementary Figure 1) against the 3 
molecular target proteins of GBM was performed using Glide XP application. 
The glide scores for i) 35 selected marine actinomycetes [27] drug-like 
molecules possessed ranged between ~ -8.5 kcal/mol to ~ -2.8 kcal/mol, ii) 5 in 
vitro and in vivo compounds [36-39] ranged from ~ -7.5 kcal/mol to ~ -3.7 
kcal/mol and iii) 4 commercial compounds [40-43] ranged from ~ -7.1 
kcal/mol to ~ -5.3 kcal/mol. By comparing their respective glide scores and 
hydrogen bond interactions, it was found that only two compounds including 
Tetracenomycin D and Chartreusin (Figure 2) out of 35 marine actinomycetes 
compounds exhibited better binding energies than the other drug-like 
molecules (Table 1 see Supplementary material). The docking scores of the 
two bioactive molecules including Tetracenomycin D and Chartreusin against 
the EphA2, EGFR and EGFRvIII are shown in Table 2 (see Supplementary 
material). All hydrogen bond interactions formed in the exterior/hydrophilic 
portion of the protein, since both the bioactive molecules are polar in nature. 
This may be due to the electric charge of the compound leading to the electric 
dipole. 
 
 
Figure 2: The 2D structure for the best two compounds. (a) 2D structure of the 
Tetracenomycin D (b) Chartreusin respectively. 
 
The amino acids Met695 and Thr692 of PDB ID: 1MQB were identified to 
form hydrogen bonds with its co-crystallized ligand Phosphoaminophosphonic 
acid-adenylate ester present in the 3D-structure of this protein. Whereas the 
docking data after simulation with Tetracenomycin D and Chartreusin revealed 
that the amino acids Met695, Asn744 and Arg743 formed hydrogen bonds with 
EphA2. The amino acids Asn744 and Arg743 are the active site residues of 
1MQB. Hence it has been observed that the binding of the two active bio 
molecules against EphA2 can block the active site region of this protein. 
Whereas for EGFR (PDB ID: 1M17) the amino acid Met769 is involved in 
hydrogen bonding with the co-crystallized ligand 6, 7-bis(2-methoxy-
ethoxy)quinazoline-4-yl]-(3- ethynylphenyl)amine [Erlotinib]. The residues 
interacted with EGFR with the two bioactive molecules were found to be 
Met769 which is found to interact with the co-crystallized ligand of 1M17. On 
the other hand for EGFRvIII (PDB ID: 1I8I) the amino acids interacted and 
formed hydrogen bonds after simulation are Asp408, Phe46, Val302, Gln301, 
Lys303, Gln412 and Trp410 out of which none of them are found to interact 
with the co-crystallized peptide of 1I8I. However these amino acids are found 
to be in close contact with EGFRvIII. Finally the simulation results revealed 
that the two bioactive molecules can efficiently block EphA2 than when 
compared to EGFR and EGFRvIII without much conformational change in the 
active site after 1ns simulation (Table 3 see Supplementary material). The 
temperature and pressure does not imply any changes in the conformation of 
the structure. The hydrogen bonds that have been formed between the protein 
and ligand after simulation are mostly present in the β-sheets and loop regions 
of the protein which contains the active site region for the catalysis of the 
substrate binding. Since they form the hydrogen bonds with by blocking the 
active site region of the protein, the docking results suggests that the two 
bioactive molecules could efficiently inhibit the functional activity of the target 
proteins of GBM.    
 
ADME or pharmacokinetics prediction of the ligands: 
Predict pharmacokinetic properties using the QikProp module of the 
Schrödinger 2009 software. QikProp settings determine which molecules are 
flagged as being dissimilar to other 95% of the known drugs. Predicted 
significant ADMET properties such as permeability through MDCK cells 
(QPlogMDCK), QikProp predicted log IC50 value for blockage of K
+ channels 
(QPlogHERG), QikProp predicted gut-blood barrier (QPPCaco) and violations 
of the Lipinski’s rule of five (LROF) were reported in Table 4 (see 
Supplementary material). The number of stars indicates the deviations from 
the 95% of the known drugs. Percent of Human Oral absorption is based on 
number of metabolites, number of rotatable bonds, logP, solubility and cell 
permeability.  
 
In accordance with Lipinski’s rule of five, QikProp was used to evaluate the 
drug-likeness of the lead molecules by assessing their physicochemical 
properties. Their molecular weights were < 500 Daltons with < 5 hydrogen 
bond donors, < 10 hydrogen bond acceptors and a log p of < 5 (Table 4 see 
Supplementary material); these properties are well within the acceptable 
range of the Lipinski rule for drug-like molecules. These compounds were 
further evaluated for their drug-like behavior through analysis of 
pharmacokinetic parameters required for absorption, distribution, metabolism, 
excretion and toxicity (ADMET) by use of QikProp. For the two bioactive 
compounds, the partition coefficient (QPlogPo/w) and water solubility 
(QPlogS), critical for estimation of absorption and distribution of drugs within 
the body, ranged between ~ 0.7 and ~ 2043, cell permeability (QPPCaco), a key 
factor governing drug metabolism and its access to biological membranes, 
ranged from 0.004 to 2050, while the bioavailability and toxicity were from ~ 
3.4 to ~ 0.4. Overall, the percentage human oral absorption for the compounds 
ranged from ~ 36 to ~ 79%. All these pharmacokinetic parameters are within 
the acceptable range defined for human use (Table 4 see Supplementary 
material), thereby indicating the selected two drug-like compounds their 
potential as drug- like molecules could be a potential inhibitor of therapeutic 
targets of GBM disease and further analysis can be performed through various 
experimental studies. Among various commercially available drugs against 
GBM, the best two bio active compounds from marine actinomycetes have 
good interactions with the GBM targets. Tetracenomycin D and Chartreusin 
have also been confirmed in both in vitro and in vivo studies for the different 
cancer treatments [27]. ADMET properties of these two compounds are under 
acceptable range. So, these drugs can be a potential inhibitor of therapeutic 
targets of GBM disease and further analysis can be performed through various 
experimental studies. 
 
Conclusion: 
In the present study we have performed comparative docking analysis of 
various compounds using Glide and the results are interpreted. EphA2 was 
identified as good target for GBM. For the first time we proposed in silico 
study to identify the potential small molecule inhibitor for EphA2, EGFR, 
EGFRvIII proteins against GBM.  
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Supplementary material: 
 
Table 1: Glide scores of the 35 marine actinomycetes, 5 in vitro and in vivo studied compounds and 4 commercially available compounds docked against EphA2 
receptor by using Schrödinger 9.0. 
Compound  ID
a Glide  Scores
b  Amino acids interacted
c
196730  -8.49826  Met695 (2.081), Thr692 (1.679), Ile619 (1.766) 
5281394  -8.42768  Met695 (2.184), Arg743 (2.214), Ala621 (1.882) 
8378  -8.40021  Asn744 (2.035), Glu623 (2.098 and 1.688), Lys778 (1.675), Ala621 (1.801), Gly759 (1.863), Glu663 (1.836) 
159572  -8.28561  Met695 (1.714), Glu696 (2.002), Ala699 (2.470), Lys646 (1.720), Asp757 (2.194) 
198084  -7.26372  Met695 (1.741), Ile619 (2.107), Lys646 (2.178) 
6436271  -7.20094  Ala621 (2.041), Arg743 (2.296), Ser756 (2.138), Lys778 (2.155), Lys646 (2.185 and 2.054) 
5282060  -6.8135  Met695 (2.496), Ala621 (1.892), Lys646 (1.727),  
656677  -6.75792  Arg743 (1.944 and 2.234), Asn744 (1.772), Asp754 (1.962), Glu663 (3.170) 
Aureoverticlluatum*  -6.55117  Lys646 (2.258), Arg743 (2.016), Asn744 (1.989), Lys778 (2.462), Asp757 (1.987) 
6438330  -6.42631  Arg743 (1.877 and 2.252), Lys646 (1.929), Asp757 (1.903) 
44418843  -6.36831  Lys778 (1.881), Asp757 (1.919), Asp739 (2.148), Arg743 (1.969), Ala621 (1.840 and 1.878) 
485475  -6.24722  Ile619 (2.134), Ala699 (2.410), Arg743 (2.090), Asn744 (1.591) 
11695330  -6.17333  Met695 (2.168), Ile619 (2.161) 
Arenicolide_A*  -6.03126  Ala621 (1.956), Arg743 (2.186, 2.160) 
Arenamide_A*  -6.02925  Lys646 (2.358), Asn744 (2.090), Asp757 (2.499) 
65556  -5.7631  Met695 (2.056), Glu693 (1.876) 
Streptopyrrolidine* -5.69317  Met695  (2.085) 
72725  -5.63672  Met695 (1.925), Glu693 (2.336) Thr692 (2.336) 
44259  -5.56443  Lys646 (1.751), Ala699 (2.018) 
5458191 -5.53807  Arg743  (2.080) 
6437838  -5.4544  Met695 (1.902), Glu623 (1.709) 
6780 -5.288  Met695  (2.074) 
5896  -5.15812  Ala699 (2.139), Ile619 (1.859) 
15939615  -5.08984  Met695 (2.066 and 2.065) 
4650 -4.48456  Met695  (1.801) 
3815 -4.21491  Met695  (2.405) 
10341 -3.941  Met695  (2.036) 
72519 -2.83629  Ala699  (1.899) 
72542  -5.25208  Met695 (2.075), Ala699 (2.182), Ile619 (1.798) 
In vivo and in vitro compounds 
370  -7.520973  Met695 (2.172 and 1.921), Lys646 (1.879), Ile619 (2.328) 
4497  -6.133939  Met695 (2.499), Lys646 (2.208, 1.708 and 1.824) 
2520  -4.633991  Glu623 (2.011), Lys646 (2.317) 
5353639 -4.290444  Lys778  (1.776) 
369312 -3.731156  Lys646  (1.986) 
Commercially available compounds 
5329012  -7.133880  Ile619 (1.972), Lys646 (1.947), Met695 (1.840) 
5426  -6.824796  Met695 (2.093 and 1.747) 
5394  -6.060448  Met695 (1.95), Glu693 (2.163) 
2578  -5.271020  Met695 (1.962 and 1.990), Lys646 (2.415) 
* Chemical structures drawn in ChemSketch (PubChem ID’s are not available), 
a Ligand IDs from pubchem database, 
b binding energies are calculated using glide 
scores, 
c residues involved in the Docking against EphA2 receptor {the distance between the amino acid and ligand are calculated in Angstrom (Å)}. 
 
Table 2: Docking results of bioactive compounds with GBM molecular target before simulation. 
PDB Id
a Compound 
(Pubchem 
ID)
b 
Docking 
Score
c 
Docking 
Energy
d 
(kcal/mol) 
Binding residues
e Hydrophillic/ 
Hydrophobic
f 
1MQB 
(EphA2) 
196730  -8.498263  -43.758053  Met695 (2.085), Thr692(1.679) and Ile619(1.766)  Hydrophilic 
5281394 -8.427678 -56.356547  Met695  (2.184),  Ala621 (1.882) and Arg743 (2.214).  Hydrophilic 
1M17  
(EGFR) 
196730  -9.383792  -44.072346  Pro770 (2.080), Met769 (2.169), Thr766 (2.011) and 
Lys721 (1.777). 
Hydrophilic 
5281394  -9.532162  -61.889792  Arg817 (1.967), Met769 (1.752), Asp831 (1.692), 
Asp831 (2.123) and Lys721 (2.054). 
Hydrophilic 
1I8I 
(EGFRvIII) 
196730  -6.177133  -41.088783  Asp408 (1.748), Phe46 (1.845), Trp410 (1.804) and 
Gln412 (2.242) 
Hydrophilic 
5281394  -8.865244  -55.201336  Asp408 (1.780), Phe46 (2.245), Val302 (1.737), 
Gln301 (1.837), Lys303 (1.979) and Gln412 (2.291). 
Hydrophilic 
a PDB id’s 1MQB- EphA2; 1M17- EGFR; 1I8I- EGFRvIII, 
b Pubchem Compound id’s 196730- Tetracenomycin D, 5281394- Chartreusin, 
c The score calculated 
for the docking, 
d The docking energy calculated in the Kcal/mol, 
e The residues involved in the Docking (The distance between the amino acid and ligands are 
calculated in Angstrom (Å)), 
f Polarity of the compound. 
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Table 3: Docking results of bioactive compounds with GBM molecular targets after simulation. 
Pdb  Id
a Compound 
(Pubchem Id)
b 
Docking 
Score
c 
Docking Energy
d 
(kcal/mol) 
Binding residues
e Hydrophillic/ 
Hydrophobic
f 
1MQB  196730  -5.194349  -40.005452  Met695 (2.053) and Asn744 (2.118)  Hydrophillic 
5281394  -7.849478  -54.326594  Met695 (1.921) and Arg743 (1.764)  Hydrophillic 
 
1M17 
 
196730 
 
-9.582641  -42.135803  Pro770 (1.992), Met769 (2.076), Thr766 (2.091) and Lys721 
(1.882) 
Hydrophilic 
 
5281394  -9.22831  -55.401185  Glu780 (2.489), Phe771 (2.268), Asp776 (1.847), Asp776 (1.847), 
Met769 (1.917) and Met769 (1.894) 
Hydrophilic 
 
1I8I 
 
196730 
 
-6.44557  -38.182559  Phe46 (1.960) and Pro44 (2.022)  Hydrophilic 
5281394  -5.152034  -50.618807  Arg55 (2.071), Tyr409 (1.898), Arg398 (2.328), Arg398 (1.682) 
and Gly326 (2.061) 
Hydrophilic 
a PDB id’s 1MQB- EphA2;1M17- EGFR; 1I8I- EGFRvIII, 
b Pubchem Compound id’s 196730- Tetracenomycin D, 5281394- Chartreusin, 
c The score calculated 
for the docking, 
d The docking energy calculated in the Kcal/mol, 
e The residues involved in the Docking {The distance between the amino acid and ligands are 
calculated in Angstrom (Å)}, 
f Polarity of the compound. 
 
Table 4: QikProp results of best two marine actinomycetes compounds, commercially available compounds, in vitro and in vivo studied compounds. 
Best two marine actinomycetes compounds 
Compound ID
a QPPMDCK
b QPlogHERG
c QPPCaco
d Stars
e  Rule of Five
f 
5281394 39.209 -5.807  95.813  2  2 
196730 0.748 -2.899  1.968  0  0 
Commercially available compounds 
5329012 723.491  -5.595  1421.445  0  0 
5426 73.075  -3.897  170.440  0  0 
5394 23.845  -3.313  60.479  0  0 
2578 2680.532  -2.220  608.912  2  0 
In vitro and in vivo  studied compounds 
370 4.348  -1.396  10.027  0  1 
4497 182.626  -4.463  397.739  0  1 
2520 499.498  -5.453  918.914  0  0 
5353639 25.237 -3.362  51.023  4  2 
369312 1787.647  -3.339  3282.329  3  0 
a Ligand IDs of pubchem database 5281394- Chartreusin, 196730- Tetracenomycin D, 5329012- Sunitinib, 5426- Thalidomide, 5394- Temozolamide, 2578- 
Carmustine, 370- Gallic acid, 4497- Nimodipine, 2520- Verapamil, 5353639- Gambogic acid, 369312- Perrilyl alcohol. 
b  Predicted apparent MDCK cell 
permeability in nm/sec (acceptable range: < 25 is poor, >500 is high ).         
c Predicted IC50 value for blockage of HERG K+ channels.(Concern below -5).  
d 
Predicted Caco-2 cell permeability in nm/s (acceptable range: < 25 is poor and > 500 is high). 
e Number of property or descriptor values that fall outside the 95% 
range of similar values for known drugs). 
f Number of violations of Lipinski’s rule of five (maximum is 4). 
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Supplementary Figure 1: The 2D structures for the 35 marine actinomycetes compounds, commercially available compounds, in vitro and in vivo studied 
compounds. (a) The 2D structures for the best 35 marine actinomycetes compounds, (b) the 2D structures for the four commercially available compounds and (c) 
the 2D structures for the five invitro and invivo studied compounds with their respective ligand identification numbers. 
 